Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML
Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.
Related Articles
Crunching the numbers for next-gen COVID-19 vaccines
BARDA tapped a team of Fred Hutch Cancer Center biostatisticians to determine the biomarkers that will serve as predictors of protective responses in next-generation COVID-19…
Clinicians’ knowledge and awareness of PROs in immune thrombocytopenia: results of a national survey
Esther Oliva, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, comments on a national survey conducted in Italy that investigated clinicians’ knowledge and…
As fire encroached, City of Hope prepared to evacuate its Duarte campus – The Cancer Letter
On Jan. 7, a bit after 6 p.m., Ravi Salgia was at his Eaton Canyon home, at the edge of Angeles National Forest. To access…
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.
Weight Changes and Heart Failure After Breast Cancer
This cohort study assesses the role of postdiagnosis and prediagnosis in weight gain in individuals with higher risk for cardiac dysfunction.
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.
FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC
The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
Short Course vs. Long Course for Neoadjuvant Radiation for… : Oncology Times
An abstract is unavailable.
